NL
SRPT icon

NKCFO LLC’s Sarepta Therapeutics SRPT Stock Holding History

NKCFO LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-275
Closed -$43K – 106
2024
Q2 		$43K Buy
+275
New +$35.3K 0.02% 81
2023
Q2 		– Sell
-1,065
Closed -$147K – 102
2023
Q1 		$147K Hold
1,065
– – 0.07% 61
2022
Q4 		$138K Buy
1,065
+300
+39% +$34.8K 0.06% 65
2022
Q3 		$85K Buy
+765
New +$77.1K 0.04% 69

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

NKCFO LLC's SRPT Position: Q3 2024 in Review

NKCFO LLC sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 275 shares — an estimated $43K sold.

NKCFO LLC first reported a position in SRPT in Q3 2022 and held it in 4 quarters. The position peaked at $147K in Q1 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • NKCFO LLC reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • NKCFO LLC sold 275 Sarepta Therapeutics shares in Q3 2024, an estimated $43K.
  • NKCFO LLC first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 4 quarters.
  • NKCFO LLC's Sarepta Therapeutics position peaked at $147K in Q1 2023.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on NKCFO LLC's 13F filing for Q3 2024, filed 17 Oct 2024.